Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04731844 · ClinicalTrials.gov registry record · Phase 2
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
A Phase 2 study of Prostate Cancer and Multiple Myeloma, sponsored by University of Rochester.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT04731844: Recruiting Phase 2 study of Prostate Cancer and Multiple Myeloma, sponsored by University of Rochester.
NCT04731844 is a Phase 2 study of Prostate Cancer and Multiple Myeloma that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 40 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04731844, a Phase 2 study of Prostate Cancer and Multiple Myeloma, is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
Primary Outcome
To estimate the proportion of participants achieving a disease-specific response following curcumin and piperine supplementation administered at a dose of 2gm/10mg(2 tablets) orally twice daily for up to 12 months. For patients with early-stage prostate cancer, response was defined as ≥50% decrease in prostate-specific antigen (PSA) from baseline, confirmed at least 4 weeks apart. For patients with MGUS or low-risk SMM, response was defined per International Myeloma Working Group (IMWG) criter
Conditions Studied
Interventions
- DRUG Curcumin plus Piperine
Study Locations (1)
New York
- University of Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-12-14 |
| Est. Completion | 2025-05-31 |
| Phase | Phase 2 |
What NCT04731844 shows while recruiting
NCT04731844 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (93% lower).
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Curcumin plus Piperine is the first listed.
NCT04731844 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04731844 about?
NCT04731844 is a clinical study titled "Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer". To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.
What is the current status of trial NCT04731844?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2021-12-14. Estimated completion is 2025-05-31.
What conditions does trial NCT04731844 study?
This clinical trial studies the following conditions: Prostate Cancer, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma (SMM).
What interventions are being tested in trial NCT04731844?
The interventions under investigation include: Curcumin plus Piperine (DRUG).
Who is sponsoring clinical trial NCT04731844?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04731844 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04731844's enrollment target sits among peer trials
40 526th of 735 higher than 201 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI